BIMI Holdings (STU:63N) Risk Assessment

View and export this data going back to . Start your Free Trial

What is BIMI Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BIMI Holdings is: No Data: Cannot be evaluated.

Competitive Comparison of BIMI Holdings's Risk Assessment

For the Pharmaceutical Retailers subindustry, BIMI Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BIMI Holdings's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BIMI Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BIMI Holdings's Risk Assessment falls into.

BIMI Holdings (STU:63N) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BIMI Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of BIMI Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

BIMI Holdings (STU:63N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BIMI Holdings Inc (STU:63N) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

BIMI:USA

Address

Chongqing Corporation Avenue, 9th Floor, Building 2, Yuzhong District, Chongqing, CHN, 400010

Website

https://www.usbimi.com

BIMI International Medical Inc is a healthcare product and provider, offering a broad range of healthcare products and related services and operates private hospitals in China. The company is engaged in four business segments, Pharmaceuticals wholesale, Medical devices wholesale, Medical services, and Pharmacy retail. It generates maximum revenue from the pharmaceuticals wholesale segment. It mainly sources its products from large state-owned pharmaceutical manufacturers and wholesalers and mid-sized or small private pharmaceutical manufacturers and wholesalers. The Company's revenues were generated in the PRC.

BIMI Holdings (STU:63N) Headlines

No Headlines